Leadership


Michael A. Caligiuri, MD
Director of The Ohio State University Comprehensive Cancer Center CEO of the James Cancer Hospital and Solove Research Institute

Clara D. Bloomfield, MD
Distinguished University Professor
Cancer Scholar and Senior Advisor

Jeff Walker, MBA
Senior Executive Director for Administration

Peter Shields, MD
Deputy Director, The Ohio State University Comprehensive Cancer Center

Richard Goldberg, MD
Physician-in-Chief, the James Cancer Hospital and Solove Research Institute

Executive Cabinet

Julian Bell, MHA, CPA
Chief Financial Officer

Stacey Bennet, JD
Assistant General Counsel of Legal Affairs

Jennifer Carlson
Assistant Vice President of Government Affairs

Steve Chaykowski
Executive Director, Development

Melissa Childress, MBA
Associate Executive Director, Business Development

Mark Conselyea, MHA
Associate Executive Director, Facilities and Space

Melissa Hall
Interim Chief Communications Officer

Kris M. Kipp, MSN, RN
Chief Nursing Officer

Chris Scarcello, MBA
Director of Research Administration

Nancy Single, PhD
Director of Clinical Research Operations

R. Michael Townsend, PhD
Chief Information Officer

Contact The James

General Inquiries


800-293-5066


Email



Address


460 W. 10th Avenue
Columbus, OH 43210


Get Your Medical Records


614-293-8657


Get Your Medical Bills


614-293-2100


Online Bill Pay



Contact Us

Latest News

Ohio State, ORIEN Could Play Role in Vice President's Cancer Moonshot Initiative

ORIEN, a network formed by Ohio State and Moffitt Cancer Center, could play an important role in the White House Cancer Moonshot initiative by facilitating the sharing of important data.

Ohio State: An Exceptional Comprehensive Cancer Center Helping Cancer Patients

Director of the OSUCCC Dr. Michael Caligiuri discusses the importance of being an NCI-designated comprehensive cancer center, where research flourishes and the best scientists and physicians want to work.

A Fireside Chat with The James CEO Dr. Michael Caligiuri

Dr. Caligiuri hosts a chat where he talked about the “exceptional” rating The James recently received from the NCI, advances in immunology & how ORIEN could play a role in the cancer “moonshot” program.